News

6MYGN : 10 Analysts Assess Myriad Genetics: What You Need To Know
Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $17.1, ...
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian ...
Nasdaq1mon
Analyst Expectations For Myriad Genetics's Future
Myriad Genetics (NASDAQ:MYGN) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...
Nasdaq7d
10 Analysts Assess Myriad Genetics: What You Need To Know
In the preceding three months, 10 analysts have released ratings for Myriad Genetics (NASDAQ:MYGN), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...